50
Participants
Start Date
December 31, 2008
Primary Completion Date
October 31, 2011
Study Completion Date
March 31, 2012
Sorafenib
Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
University of California Davis Cancer Center, Sacramento
Collaborators (1)
Bayer
INDUSTRY
University of California, Davis
OTHER